Form 4: Xencor CFO Granted Equity Awards

Xencor Inc.'s Senior Vice President and CFO, Bart Jan Cornelissen, was granted 19,458 restricted stock units and options to purchase 116,750 shares.

Summary

• Bart Jan Cornelissen, Xencor Inc.'s SR. VICE PRESIDENT & CFO, was granted equity awards on March 2, 2026.
• The awards include 19,458 Restricted Stock Units (RSUs) and stock options to purchase 116,750 shares of common stock.
• The RSUs vest in three equal annual installments, with 1/3 vesting on the first, second, and third anniversaries of the grant date, subject to continuous service.
• The stock options have an exercise price of $12.30 and vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting monthly over the subsequent three years, also contingent on continuous service.
• Following these transactions, Cornelissen beneficially owns 81,914 shares of common stock, which includes 1,108 shares acquired on June 10, 2025, through the Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and healthy practice for public companies.

Positives

• Grant of 19,458 Restricted Stock Units (RSUs) to the CFO, aligning executive interests with shareholder value.
• Grant of options to purchase 116,750 shares of common stock at an exercise price of $12.30, providing long-term incentive.
• Equity awards are contingent on continuous service, promoting executive retention and stability within the company's leadership.

Risks

• The vesting of both the Restricted Stock Units and stock options is subject to the Reporting Person's continuous service to the Issuer, meaning the awards could be forfeited if employment ceases before vesting dates.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align the interests of executives with those of shareholders by incentivizing long-term performance and retention, which is crucial in a sector characterized by long development cycles and high R&D costs.

Comparison to Industry Standards

• Equity compensation for senior executives like a CFO is a common practice across the biotech industry.
• Companies such as Amgen, Gilead Sciences, and Biogen frequently utilize similar RSU and stock option grants with multi-year vesting schedules to retain key talent and motivate performance.
• The vesting schedule over three to four years for these awards is typical for ensuring long-term commitment and aligning executive incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon vesting/exercise, but also increased alignment of executive incentives with long-term shareholder value creation.
• Employees: Reflects standard executive compensation practices, potentially setting a benchmark for other senior roles within the company.

Next Steps

• Vesting of 1/3 of RSUs on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on continuous service.
• Vesting of 25% of stock options on March 2, 2027, with monthly vesting thereafter until March 2, 2030, contingent on continuous service.
• Potential exercise of stock options by the CFO before the expiration date of March 2, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard practice to align management's interests with shareholders. While it indicates continued commitment from the CFO, it does not present new fundamental information about the company's operations or financial performance that would warrant a change in investment stance. It reinforces a 'hold' recommendation, as it's a neutral, expected event in corporate governance.

Keywords

Xencor, XNCR, Form 4, insider transaction, equity grant, restricted stock units, RSUs, stock options, executive compensation, CFO, Bart Jan Cornelissen